Zhong Guo Jing Ji Wang·2025-12-31 09:49Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, closing at 40.70 yuan with a drop of 3.85%, indicating it is in a state of breaking below its initial public offering price [1] Group 1: IPO and Financials - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest price recorded on the first day of trading was 188.00 yuan, marking the peak since its listing [1] - The total funds raised from the IPO amounted to 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original target by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including pharmaceutical intermediates, raw materials, and R&D center expansion [1] Group 2: Shareholder Returns - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares held [2] - The record date for this equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2] Group 3: Management - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin holding Canadian permanent residency [2]